BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33905040)

  • 21. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
    Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q
    Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes.
    Sampathi S; Acharya P; Zhao Y; Wang J; Stengel KR; Liu Q; Savona MR; Hiebert SW
    Nucleic Acids Res; 2019 May; 47(8):3921-3936. PubMed ID: 30805632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
    Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
    Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
    Ge H; Yao Y; Jiang Y; Wu X; Wang Y
    Oral Dis; 2022 Apr; 28(3):611-620. PubMed ID: 33503275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
    McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
    Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
    Cheng ZJ; Miao DL; Su QY; Tang XL; Wang XL; Deng LB; Shi HD; Xin HB
    Acta Pharmacol Sin; 2019 Jun; 40(6):814-822. PubMed ID: 30446732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
    Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
    Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.
    Zhang Z; Peng H; Wang X; Yin X; Ma P; Jing Y; Cai MC; Liu J; Zhang M; Zhang S; Shi K; Gao WQ; Di W; Zhuang G
    Mol Cancer Ther; 2017 Sep; 16(9):1739-1750. PubMed ID: 28572168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.
    Kwiatkowski N; Zhang T; Rahl PB; Abraham BJ; Reddy J; Ficarro SB; Dastur A; Amzallag A; Ramaswamy S; Tesar B; Jenkins CE; Hannett NM; McMillin D; Sanda T; Sim T; Kim ND; Look T; Mitsiades CS; Weng AP; Brown JR; Benes CH; Marto JA; Young RA; Gray NS
    Nature; 2014 Jul; 511(7511):616-20. PubMed ID: 25043025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
    Wong RWJ; Ngoc PCT; Leong WZ; Yam AWY; Zhang T; Asamitsu K; Iida S; Okamoto T; Ueda R; Gray NS; Ishida T; Sanda T
    Blood; 2017 Nov; 130(21):2326-2338. PubMed ID: 28978570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.
    Nilson KA; Guo J; Turek ME; Brogie JE; Delaney E; Luse DS; Price DH
    Mol Cell; 2015 Aug; 59(4):576-87. PubMed ID: 26257281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer.
    Wang J; Li Z; Mei H; Zhang D; Wu G; Zhang T; Lin Z
    Anticancer Drugs; 2019 Jun; 30(5):466-474. PubMed ID: 30694816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma.
    Chen HD; Huang CS; Xu QC; Li F; Huang XT; Wang JQ; Li SJ; Zhao W; Yin XY
    Int J Biol Sci; 2020; 16(7):1207-1217. PubMed ID: 32174795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942.
    Sava GP; Fan H; Fisher RA; Lusvarghi S; Pancholi S; Ambudkar SV; Martin LA; Charles Coombes R; Buluwela L; Ali S
    Oncogene; 2020 Jan; 39(3):651-663. PubMed ID: 31530935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
    Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
    Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation.
    Juric V; Hudson L; Fay J; Richards CE; Jahns H; Verreault M; Bielle F; Idbaih A; Lamfers MLM; Hopkins AM; Rehm M; Murphy BM
    Cell Death Dis; 2021 Aug; 12(8):763. PubMed ID: 34344865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
    Shi CS; Kuo KL; Chen MS; Chow PM; Liu SH; Chang YW; Lin WC; Liao SM; Hsu CH; Hsu FS; Chang HC; Huang KH
    Cells; 2019 Nov; 8(11):. PubMed ID: 31752390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of CDK7 inhibitor on MYCN-amplified retinoblastoma.
    Xu H; Xiao L; Chen Y; Liu Y; Zhang Y; Gao Y; Man S; Yan N; Zhang M
    Biochim Biophys Acta Gene Regul Mech; 2023 Sep; 1866(3):194964. PubMed ID: 37536559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.
    Rasool RU; Natesan R; Deng Q; Aras S; Lal P; Sander Effron S; Mitchell-Velasquez E; Posimo JM; Carskadon S; Baca SC; Pomerantz MM; Siddiqui J; Schwartz LE; Lee DJ; Palanisamy N; Narla G; Den RB; Freedman ML; Brady DC; Asangani IA
    Cancer Discov; 2019 Nov; 9(11):1538-1555. PubMed ID: 31466944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
    Pelish HE; Liau BB; Nitulescu II; Tangpeerachaikul A; Poss ZC; Da Silva DH; Caruso BT; Arefolov A; Fadeyi O; Christie AL; Du K; Banka D; Schneider EV; Jestel A; Zou G; Si C; Ebmeier CC; Bronson RT; Krivtsov AV; Myers AG; Kohl NE; Kung AL; Armstrong SA; Lemieux ME; Taatjes DJ; Shair MD
    Nature; 2015 Oct; 526(7572):273-276. PubMed ID: 26416749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.